Pathstone Holdings
LUCD icon

Pathstone Holdings’s Lucid Diagnostics LUCD Stock Holding History

Pathstone Holdings’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,958
Closed -$16.3K – 2290
2025
Q4 		$16.3K Buy
+14,958
New +$16.7K ﹤0.01% 2212

Other funds holding LUCD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Pathstone Holdings's LUCD Position: Q1 2026 in Review

Pathstone Holdings sold out of Lucid Diagnostics (LUCD) in Q1 2026, closing a stake of 14,958 shares — an estimated $16.3K sold.

Pathstone Holdings first reported a position in LUCD in Q4 2025 and held it in 1 quarter. The position peaked at $16.3K in Q4 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

  • Pathstone Holdings reported no remaining Lucid Diagnostics position as of Q1 2026 after selling out during the quarter.
  • Pathstone Holdings sold 14,958 Lucid Diagnostics shares in Q1 2026, an estimated $16.3K.
  • Pathstone Holdings first reported a position in Lucid Diagnostics in Q4 2025 and held it in 1 quarter.
  • Pathstone Holdings's Lucid Diagnostics position peaked at $16.3K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Pathstone Holdings's 13F filing for Q1 2026, filed 11 May 2026.